{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T22:45:58Z","timestamp":1776465958487,"version":"3.51.2"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,12]]},"abstract":"<jats:p>COVID-19 disrupts the balance between coagulation and fibrinolysis. Especially in the clinical course of serious disease, plasminogen activator inhibitor-1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), and tissue plasminogen activator levels increase in association with hypercoagulable state and hypofibrinolysis. This explains the increased incidence of thrombosis seen in COVID-19 infection. In this study, we aimed to examine the changes in PAI-1 and TAFI levels of COVID-19 patients. Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Di\u015fkapi Yildirim Beyazit Training and Research Hospital\u2014Ankara Turkey, between April 1 and May 7, 2021. Patients who were diagnosed with COVID-19 were included in this retrospective study. TAFI and PAI-1 levels were analyzed from the samples that had been stored at \u201380 \u00b0C formerly. One hundred thirty-five patients diagnosed with COVID-19 and followed up in the service or intensive care unit were included in the study. Thirty-four (25.2%) patients required follow-up in the intensive care unit. Mortality rate was 10.4%, the coagulation tests of these patients were also compared. PA1-1 levels were found to be statistically significantly higher in intensive care unit patients (median: 133 pg\/mL vs 31 pg\/mL; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), and there was no significant difference in TAFI levels (median:7.31\u2009ng\/mL vs 9.80\u2009ng\/mL; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.171) between the 2 groups. TAFI levels were found to be higher in patients who died. In COVID-19 infection, as the severity of the disease increases, the coagulation balance deteriorates and eventually a hypercoagulable state occurs with an increase in PAI-1 and TAFI levels. Markers such as PAI and TAFI can be illuminating in further studies in determining prognosis and mortality and developing new treatment options.<\/jats:p>","DOI":"10.1097\/md.0000000000037802","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T19:00:14Z","timestamp":1712948414000},"page":"e37802","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A challenging issue in COVID-19 infection: The relationship between PA1-1 and TAFI levels in patients with coagulation disorder: A retrospective and observational study"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-712X","authenticated-orcid":false,"given":"Nilgun","family":"Altin","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Di\u015fkapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinar","family":"Ti\u011flio\u011flu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sancaktepe Prof. Dr. Sehit Ilhan Varank Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulay Unver","family":"Ulusoy","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Di\u015fkapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi Nuri","family":"Aydin","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Health Sciences, Di\u015fkapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130rem","family":"Kar","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Ankara University, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Busra","family":"Karakoc","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Di\u015fkapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulten","family":"Utebey","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Reanimation, University of Health Sciences, Di\u015fkapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250618","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet (London, England)"},{"key":"R2-20250618","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00907-0","article-title":"Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis.","volume":"13","author":"Meng","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R3-20250618","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.","volume":"94","author":"Yang","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R4-20250618","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/jama.2020.3633","article-title":"Care for critically ill patients with COVID-19.","volume":"323","author":"Murthy","year":"2020","journal-title":"JAMA"},{"key":"R5-20250618","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jamcollsurg.2021.02.019","article-title":"Fibrinolysis shutdown in COVID-19: clinical manifestations, molecular mechanisms, and therapeutic implications.","volume":"232","author":"Meizoso","year":"2021","journal-title":"J Am Coll Surg"},{"key":"R6-20250618","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R7-20250618","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/jth.14849","article-title":"Thromboinflammation and the hypercoagulability of COVID-19.","volume":"18","author":"Connors","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R8-20250618","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/17474086.2023.2288154","article-title":"Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection.","volume":"16","author":"Boccatonda","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"R9-20250618","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.3390\/jcm11144112","article-title":"Platelet count in patients with SARS-CoV-2 infection: a prognostic factor in COVID-19.","volume":"11","author":"Boccatonda","year":"2022","journal-title":"J Clin Med"},{"key":"R10-20250618","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/cts.12907","article-title":"COVID-19 and venous thromboembolism in intensive care or medical ward.","volume":"13","author":"Avruscio","year":"2020","journal-title":"Clin Transl Sci"},{"key":"R11-20250618","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1055\/s-0040-1714350","article-title":"COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure.","volume":"120","author":"Spiezia","year":"2020","journal-title":"Thromb Haemost"},{"key":"R12-20250618","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood.V3.10.1167.1167","article-title":"Fibrinolysis. Its mechanism and significance.","volume":"3","author":"Macfarlane","year":"1948","journal-title":"Blood"},{"key":"R13-20250618","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/ijms22052721","article-title":"A narrative review on plasminogen activator inhibitor-1 and its (Patho) physiological role: to target or not to target?","volume":"22","author":"Sillen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R14-20250618","doi-asserted-by":"crossref","first-page":"16603","DOI":"10.1074\/jbc.271.28.16603","article-title":"TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.","volume":"271","author":"Bajzar","year":"1996","journal-title":"J Biol Chem"},{"key":"R15-20250618","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1111\/jth.15016","article-title":"Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis.","volume":"18","author":"Nougier","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R16-20250618","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"key":"R17-20250618","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19.","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20250618","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID- 19.","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"R19-20250618","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.bja.2020.12.010","article-title":"Impaired fibrinolysis in critically ill COVID-19 patients.","volume":"126","author":"Bachler","year":"2021","journal-title":"Br J Anaesth"},{"key":"R20-20250618","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R21-20250618","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2021.12.012","article-title":"Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19?","volume":"210","author":"Nielsen","year":"2022","journal-title":"Thromb Res"},{"key":"R22-20250618","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation.","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"R23-20250618","first-page":"2377","article-title":"Hypofibrinolysis is associated with the severity of COVID-19 Infection: the role of obesity.","volume":"37","author":"Oran","year":"2021","journal-title":"Acta Medica Mediterranea"},{"key":"R24-20250618","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.2741\/3864","article-title":"An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.","volume":"16","author":"Heylen","year":"2011","journal-title":"Front Biosci (Landmark edition)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T16:02:20Z","timestamp":1750262540000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":24,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037802","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]}}}